close read more

Our key Figures

22,000 employees

in 149 countries, including 5,000 in France.

5 major R&D areas

cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes.

100 Million patients

treated daily with Servier medicinal products and generics.

33 drug candidates

in research and development, including 23 new molecular entities.

15 international centers of clinical development

and 3 research centers.

16 chemical and pharmaceutical production sites

producing chemicals and pharmaceuticals worldwide.

€4,2 billion euros in revenue

comprising €2.9 billion for branded drugs and €1.3 billion for generics.

25 % of turnover from Servier drugs is invested in R&D

excluding generics.

No. 2 pharmaceutical company in France

no. 33 in the world; 3 research centres including 2 in France.

No.1 in cardiology in France

no. 2 in Europe, No. 5 in the world.


2nd leading preferred partner for research centers conducting clinical trials

According to CenterWatch rankings from March 2017, based on a total of 23 pharmaceutical companies


Servier earned the highest score of A3++

As in previous years, this high score represents excellence in honoring financial commitments.


Participation reached 36,6% of the trade balance surplus in France

In pharmaceuticals and fine chemicals, amouting to €1.4 billion.